UK markets close in 2 hours 31 minutes

BioMarin Pharmaceutical Inc. (0HNC.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
89.36+5.21 (+6.19%)
As of 3:20PM GMT. Market open.
Currency in USD

Valuation measures

Market cap (intra-day) 516.27B
Enterprise value 315.11B
Trailing P/E 19.73
Forward P/E 1N/A
PEG ratio (5-yr expected) 1N/A
Price/sales (ttm)8.75
Price/book (mrq)3.96
Enterprise value/revenue 38.12
Enterprise value/EBITDA 61,260.21

Trading information

Stock price history

Beta (5Y monthly) 0.60
52-week change 3N/A
S&P500 52-week change 323.92%
52-week high 383.10
52-week low 383.10
50-day moving average 3N/A
200-day moving average 3N/A

Share statistics

Avg vol (3-month) 3N/A
Avg vol (10-day) 3N/A
Shares outstanding 5178.06M
Float 180.44M
% held by insiders 10.61%
% held by institutions 1100.25%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2020
Most-recent quarter (mrq)31 Dec 2020

Profitability

Profit margin 46.18%
Operating margin (ttm)-4.93%

Management effectiveness

Return on assets (ttm)-1.09%
Return on equity (ttm)23.77%

Income statement

Revenue (ttm)1.86B
Revenue per share (ttm)10.29
Quarterly revenue growth (yoy)-0.50%
Gross profit (ttm)708.07M
EBITDA 11.99M
Net income avi to common (ttm)859.1M
Diluted EPS (ttm)4.53
Quarterly earnings growth (yoy)47.10%

Balance sheet

Total cash (mrq)1.07B
Total cash per share (mrq)5.86
Total debt (mrq)1.08B
Total debt/equity (mrq)26.18
Current ratio (mrq)4.76
Book value per share (mrq)22.59

Cash flow statement

Operating cash flow (ttm)N/A
Levered free cash flow (ttm)N/A